Mendus AB (“Mendus” publ: IMMU.ST), a biopharmaceutical company transforming immunotherapies for myeloid blood cancers, today announced the appointment of the members of the Nomination Committee in accordance with the principles for appointing the Nomination Committee adopted at the Annual General Meeting on May 6, 2025. The members of Mendus’ Nomination Committee shall be appointed by the four largest shareholders, as of the last banking day in September, who wish to appoint a representative. If fewer than four shareholders choose to exercise this right, the Nomination Committee shall consist of fewer members.
Sven Andreasson, Chairman of Mendus’ Board of Directors, has contacted the Company's largest shareholders in order to appoint the Nomination Committee. The following members have been appointed by the three largest shareholders who have accepted the invitation to serve on the Nomination Committee:
Erik Esveld, appointed by Van Herk Investments B.V.
Cecilia Stureborg von Schéele, appointed by Flerie Invest AB
Mats Andersson, appointed by Holger Blomstrands Byggnads AB
The Nomination Committee represents approximately 58.56 per cent of the total number of shares and votes in the company as of September 30, 2026.
The Annual General Meeting will be held on May 11, 2027, in Stockholm.
Information regarding the work of the Nomination Committee is available on Mendus' website www.mendus.com.
Shareholders wishing to submit proposals to the Nomination Committee are requested to send their proposals by e-mail to info@mendus.com or by postto Mendus AB (publ), Västra Trädgårdsgatan 15, 111 53 Stockholm, Sweden.